Ilaris® Effects in Schnitzler Syndrome (ILESCH) (ILESCH)
A Multi-center, Double-blind, Placebo-controlled Phase II Study of the Efficacy and Safety of Canakinumab in Subjects With Schnitzler Syndrome
Sponsor: Charite University, Berlin, Germany
This PHASE2 trial investigates Schnitzler Syndrome and is currently completed. Charite University, Berlin, Germany leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
▶ Show 2 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Jul 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Charite University, Berlin, Germany
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .